US regulatory status: approved. Molecular target: Beta-2 adrenergic receptor.
- Target
- Beta-2 adrenergic receptor
- Mechanism
- Beta-2 adrenergic receptor agonist
pharma · Melanoma · Ovarian Cancer
Sandoz (Japan)
Sandoz Pty Ltd
Sandoz (Japan) drug portfolio — 22 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Basel, CH HQ
17,495 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Basel, CH
- Employees
- 17,495
- Programs
- 4
- Drugs
- 22
- Patents
- 0
Sandoz (Japan) pipeline
Portfolio lens on 22 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Sandoz (Japan) drug portfolio — 22 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
anti-melanoma mab fragments
Various (V09)Various (V09) compound in Sandoz (Japan)'s portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to Sandoz (Japan) in public FDA and regional records. Mechanism: Norepinephrine transporter inhibitor.
- Mechanism
- Norepinephrine transporter inhibitor
-
Development asset linked to Sandoz (Japan) in public FDA and regional records.
-
Development asset linked to Sandoz (Japan) in public FDA and regional records. Mechanism: D2-like dopamine receptor agonist.
- Mechanism
- D2-like dopamine receptor agonist
-
entacapone
Nervous system (N04)US regulatory status: approved. Molecular target: Catechol O-methyltransferase.
- Target
- Catechol O-methyltransferase
- Mechanism
- Catechol O-methyltransferase inhibitor
-
Development asset linked to Sandoz (Japan) in public FDA and regional records.
-
Development asset linked to Sandoz (Japan) in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA topoisomerase II.
- Target
- DNA topoisomerase II
- Mechanism
- DNA topoisomerase II inhibitor
-
Development asset linked to Sandoz (Japan) in public FDA and regional records.
-
fluticasone furoate
Respiratory system (R03)US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Sandoz (Japan) in public FDA and regional records.
-
Development asset linked to Sandoz (Japan) in public FDA and regional records.
-
Development asset linked to Sandoz (Japan) in public FDA and regional records.
-
Development asset linked to Sandoz (Japan) in public FDA and regional records.
-
Development asset linked to Sandoz (Japan) in public FDA and regional records.
-
Development asset linked to Sandoz (Japan) in public FDA and regional records.
-
olaparib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: PARP 1, 2 and 3.
- Target
- PARP 1, 2 and 3
- Mechanism
- PARP 1, 2 and 3 inhibitor
-
US regulatory status: approved. Molecular target: Peroxisome proliferator-activated receptor gamma.
- Target
- Peroxisome proliferator-activated receptor gamma
- Mechanism
- Peroxisome proliferator-activated receptor gamma agonist
-
Development asset linked to Sandoz (Japan) in public FDA and regional records.
-
Development asset linked to Sandoz (Japan) in public FDA and regional records.
-
Development asset linked to Sandoz (Japan) in public FDA and regional records.